Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

Targets for Anti-HIV-1 Agents as Personalized HIV Therapy: A Review Study

Document Type : Review Article

Authors

Mina Jafari 1
Ava Shamipak 1
Fateme Shahsavari 1
Armin Nikdehqan 2
Paniz Hajihossein 2

1 Department of Biology, Faculty of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran

2 Department of Biology, Faculty of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran.

https://doi.org/10.22034/pmj.2023.2011750.1016
Abstract
The enormous genetic variety of the viral population harbored by the patient and the large volume of therapeutic alternatives characterize HIV therapy. Each patient and period has its viral population. The enormous number of therapy possibilities makes selecting an ideal or near-optimal therapy challenging, especially among therapy-experienced patients. Over the last decade, computer-based medication selection that measures viral resistance to pharmaceuticals has become a norm for HIV patients. We explore the qualities of available systems and the field's viewpoints.

Keywords

HIV therapy
Anti-HIV-1 Agents
HIV Medication Resistance
Subjects
  1. Shah R, Mehta R. Why Covid-19 Vaccine Still not Invented to Relieve the Globe from Pandemic. Journal of Applied Pharmacy. 2021.
  2. Piri Gharaghie T, Hajimohammadi S. Comparison of anti-candida effects of aqueous, ethanolic extracts and essential oil of E. angustifolia with fluconazole on the growth of clinical strains of Candida. New Cellular and Molecular Biotechnology Journal. 2021 Jul 10;11(43):25-38.
  3. Piri Gharaghie T, Doosti A, Mirzaei SA. Detection of T6SS secretory system and membrane purine involved in antibiotic resistance in multidrug-resistant Acinetobacter baumannii isolates. Journal of Microbial World. 2021 May 22;14(1):47-58.
  4. Piri-Gharaghie T, Doosti A, Mirzaei SA. Novel adjuvant nano-vaccine induced immune response against Acinetobacter baumannii. AMB Express. 2023 Dec;13(1):1-6.
  5. Piri-Gharaghie T, Ghajari G, Hassanpoor M, Jegargoshe-Shirin N, Soosanirad M, Khayati S, Farhadi-Biregani A, Mirzaei A. Investigation of antibacterial and anticancer effects of novel niosomal formulated Persian Gulf Sea cucumber extracts. Heliyon. 2023 Mar 1;9(3).
  6. Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cellular signalling. 2020 Oct 1;74:109721.
  7. Taghiloo S, Ghajari G, Zand Z, Kabiri‐Samani S, Kabiri H, Rajaei N, Piri‐Gharaghie T. Designing Alginate/Chitosan Nanoparticles Containing Echinacea angustifolia: A Novel Candidate for Combating Multidrug‐Resistant Staphylococcus aureus. Chemistry & Biodiversity. 2023 Jul;20(7):e202201008.
  8. Asadipour E, Asgari M, Mousavi P, Piri‐Gharaghie T, Ghajari G, Mirzaie A. Nano‐Biotechnology and Challenges of Drug Delivery System in Cancer Treatment Pathway. Chemistry & Biodiversity. 2023 Mar 1:e202201072.
  9. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483-9.
  10. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). Journal of antimicrobial chemotherapy. 2010 Feb 1;65(2):202-12.
  11. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. Journal of Clinical Oncology. 2015 Aug 8;33(23):2563.
  12. Aranzana MJ, Decroocq V, Dirlewanger E, Eduardo I, Gao ZS, Gasic K, Iezzoni A, Jung S, Peace C, Prieto H, Tao R. Prunus genetics and applications after de novo genome sequencing: achievements and prospects. Horticulture research. 2019 Dec 1;6.
  13. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases. 2003 Jul 1;37(1):113-28.
  14. Shanteau J. How much information does an expert use? Is it relevant?. Acta psychologica. 1992 Oct 1;81(1):75-86.
  15. McNerney R, Maeurer M, Abubakar I, Marais B, Mchugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. Journal of Infectious Diseases. 2012 May 15;205(suppl_2):S147-58.
  16. Hirsch MS, Conway B, Richard TD, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. Jama. 1998 Jun 24;279(24):1984-91.
  17. Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nature Reviews Cancer. 2012 Jul;12(7):494-501.
  18. Kleinman, S., Busch, M.P., Murphy, E.L., Shan, H., Ness, P., Glynn, S.A. and National Heart, Lung, and Blood InLengauer T, Pfeifer N, Kaiser R. Personalized HIV therapy to control drug resistance. Drug Discovery Today: Technologies. 2014 Mar 1;11:57-64.stitute Recipient Epidemiology and Donor Evaluation Study (REDS‐III), 2014. The N ational H eart, L ung, and B lood I nstitute R ecipient E pidemiology and D onor E valuation S tudy (REDS‐III): a research program striving to improve blood donor and transfusion recipient outcomes. Transfusion, 54(3pt2), pp.942-955.
  19. Lasater K. Clinical judgment development: Using simulation to create an assessment rubric. Journal of nursing education. 2007 Nov 1;46(11):496-503.
  20. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PloS one. 2009 Mar 6;4(3):e4724.
  21. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct‐acting antivirals. Hepatology. 2013 Jul;58(1):428-38.
  22. Creager AN, Gaudillière JP. Meanings in Search of Experiments and Vice-versa: the Invention of Allosteric regulation in Paris and Berkeley, 1959-1968. Historical Studies in the Physical and Biological Sciences. 1996 Jan 1;27(1):1-89.
  23. Schätz B, Hölzl F, Lundkvist T. Design-space exploration through constraint-based model-transformation. In2010 17th IEEE International conference and workshops on engineering of computer based systems 2010 Mar 22 (pp. 173-182). IEEE.
  24. Vriend NJ. An illustration of the essential difference between individual and social learning, and its consequences for computational analyses. Journal of economic dynamics and control. 2000 Jan 1;24(1):1-9.
  25. Van den Hoecke S, Ballegeer M, Vrancken B, Deng L, Job ER, Roose K, Schepens B, Van Hoecke L, Lemey P, Saelens X. In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression. Mbio. 2021 Aug 31;12(4):10-128.
  26. Chizhmakov IV, Geraghty FM, Ogden DC, Hayhurst A, Antoniou M, Hay AJ. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. The Journal of physiology. 1996 Jul 15;494(2):329-36.
  27. Raposo LM, Arruda MB, de Moraes Brindeiro R, Nobre FF. SIRA-HIV: A User-friendly System to Evaluate HIV-1 Drug Resistance from Next-generation Sequencing Data. InBIOINFORMATICS 2020 (pp. 93-100).
  28. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clinical infectious diseases. 2006 Jun 1;42(11):1608-18.
  29. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, Kimmel AD, Freedberg KA. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Annals of internal medicine. 2001 Mar 20;134(6):440-50.
  30. Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Annali dell'Istituto superiore di sanita. 2010;46:5-14.
  31. Ji H, Shu W, Burling FT, Jiang S, Lu M. Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. Journal of virology. 1999 Oct 1;73(10):8578-86.
  32. Hu WS, Hughes SH. HIV-1 reverse transcription. Cold Spring Harbor perspectives in medicine. 2012 Oct 1;2(10):a006882.
  33. Schleper C, Kubo K, Zillig W. The particle SSV1 from the extremely thermophilic archaeon Sulfolobus is a virus: demonstration of infectivity and of transfection with viral DNA. Proceedings of the National Academy of Sciences. 1992 Aug 15;89(16):7645-9.
  34. Sundquist WI, Kräusslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harbor perspectives in medicine. 2012 Mar 13:a006924.
  35. Teixeira C, Gomes JR, Gomes P, Maurel F. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. European journal of medicinal chemistry. 2011 Apr 1;46(4):979-92.
  36. Mahajan SD, Aalinkeel R, Law WC, Reynolds JL, Nair BB, Sykes DE, Yong KT, Roy I, Prasad PN, Schwartz SA. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. International journal of nanomedicine. 2012 Oct 5:5301-14.
  37. Sang P, Tian SH, Meng ZH, Yang LQ. Anti-HIV drug repurposing against SARS-CoV-2. RSC advances. 2020;10(27):15775-83
  38. Barghash RF, Fawzy IM, Chandrasekar V, Singh AV, Katha U, Mandour AA. In silico modeling as a perspective in developing potential vaccine candidates and therapeutics for COVID-19. Coatings. 2021 Oct 20;11(11):1273..
  39. Schomburg D, Schomburg I. SARS coronavirus main proteinase 3.4. 22.69. Class 3.4–6 Hydrolases, Lyases, Isomerases, Ligases: EC 3.4–6. 2013:65-97.
  40. Shivanika C, Kumar D, Ragunathan V, Tiwari P, Sumitha A. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. Journal of biomolecular structure & dynamics. 2020:1.
  41. Ibrahim MA, Abdelrahman AH, Allemailem KS, Almatroudi A, Moustafa MF, Hegazy ME. In silico evaluation of prospective anti-COVID-19 drug candidates as potential SARS-CoV-2 main protease inhibitors. The Protein Journal. 2021 Jun;40:296-309.
  42. Nepali K, Sharma R, Sharma S, Thakur A, Liou JP. Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. Journal of Biomedical Science. 2022 Sep 6;29(1):65.
  43. Kang D, Chen W, Zhan P, Liu X. “Old Dogs with New Tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. Molecular BioSystems. 2014;10(8):1998-2022.
  44. Heredia A, Le N, Gartenhaus RB, Sausville E, Medina-Moreno S, Zapata JC, Davis C, Gallo RC, Redfield RR. Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proceedings of the National Academy of Sciences. 2015 Jul 28;112(30):9412-7.
  45. De Amici M, Dallanoce C, Holzgrabe U, Tränkle C, Mohr K. Allosteric ligands for G protein‐coupled receptors: A novel strategy with attractive therapeutic opportunities. Medicinal research reviews. 2010 May;30(3):463-549.
  46. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, Vassart G, Doms RW, Parmentier M. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood, The Journal of the American Society of Hematology. 1999 Sep 15;94(6):1899-905.
  47. Qiu Z, Chong H, Yao X, Su Y, Cui S, He Y. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target. Aids. 2015 Jun 1;29(9):1015-24.
  48. Tan JJ, Cong XJ, Hu LM, Wang CX, Jia L, Liang XJ. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug discovery today. 2010 Mar 1;15(5-6):186-97.
  49. Rao KS, Ghorpade A, Labhasetwar V. Targeting anti-HIV drugs to the CNS. Expert opinion on drug delivery. 2009 Aug 1;6(8):771-84.
  50. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 Dec 7;75(23):2087-96.
  51. Clercq ED. New anti‐HIV agents and targets. Medicinal Research Reviews. 2002 Nov;22(6):531-65.
  52. Demarest J, Underwood M, St. Clair M, Dorey D, Brown D, Zolopa A. Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naïve Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. AIDS Research and Human Retroviruses. 2018 Apr 1;34(4):343-6.
  53. Maskew M, MacPhail P, Menezez C, Rubel D. Lost to follow up–contributing factors and challenges in South African patients on antiretroviral therapy. South African medical journal. 2007 Oct 31;97(9):853-7.
  54. Johansson O. Disturbance of the immune system by electromagnetic fields—A potentially underlying cause for cellular damage and tissue repair reduction which could lead to disease and impairment. Pathophysiology. 2009 Aug 1;16(2-3):157-77.
  55. Sosnik A, Augustine R. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them. Advanced drug delivery reviews. 2016 Aug 1;103:105-20.
  56. Bassand C, Villois A, Gianola L, Laue G, Ramazani F, Riebesehl B, Sanchez-Felix M, Sedo K, Ullrich T, Duvnjak Romic M. Smart design of patient-centric long-acting products: from preclinical to marketed pipeline trends and opportunities. Expert opinion on drug delivery. 2022 Oct 3;19(10):1265-83.
  57. Kevadiya BD, Ottemann B, Mukadam IZ, Castellanos L, Sikora K, Hilaire JR, Machhi J, Herskovitz J, Soni D, Hasan M, Zhang W. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics. 2020;10(2):630.
  58. Asahchop EL, Meziane O, Mamik MK, Chan WF, Branton WG, Resch L, Gill MJ, Haddad E, Guimond JV, Wainberg MA, Baker GB. Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. Retrovirology. 2017 Dec;14:1-7.
  59. Alam C, Whyte-Allman SK, Omeragic A, Bendayan R. Role and modulation of drug transporters in HIV-1 therapy. Advanced drug delivery reviews. 2016 Aug 1;103:121-43.
  60. Tjagvad C. Addictive medication in relation to drug treatment and overdose death.
  61. Andre M, Nair M, Raymond AD. HIV Latency and Nanomedicine Strategies for Anti-HIV Treatment and Eradication. Biomedicines. 2023 Feb 18;11(2):617.
  62. Appay V, Sauce D. Immune activation and inflammation in HIV‐1 infection: causes and consequences. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2008 Jan;214(2):231-41.
  63. Wake DT, Smith DM, Kazi S, Dunnenberger HM. Pharmacogenomic clinical decision support: a review, how‐to guide, and future vision. Clinical Pharmacology & Therapeutics. 2022 Jul;112(1):44-57.
  64. Musen MA, Tu SW, Das AK, Shahar Y. EON: A component-based approach to automation of protocol-directed therapy. Journal of the American Medical Informatics Association. 1996 Nov 1;3(6):367-88.
  65. Molitch ME, Beck JR, Dreisman M, Gottlieb JE, Paukerj SG. The cold thyroid nodule: an analysis of diagnostic and therapeutic options. Endocrine reviews. 1984 Apr 1;5(2):185-99.
  66. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug discovery today. 2021 Feb 1;26(2):511-24.
  67. Kazemi A, Salmani H, Shakibafard A, Fatehi F. New and emerging mobile technologies for healthcare (mHealth): A horizon scanning study. Frontiers in Health Informatics. 2019 Aug 21;8(1):17.
  68. Kushniruk AW, Patel VL. Cognitive and usability engineering methods for the evaluation of clinical information systems. Journal of biomedical informatics. 2004 Feb 1;37(1):56-7
  69. Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype‐phenotype relationships. Journal of Comparative Neurology. 2007 Oct 1;504(4):329-45.
  70. Lengauer T, Pfeifer N, Kaiser R. Personalized HIV therapy to control drug resistance. Drug Discovery Today: Technologies. 2014 Mar 1;11:57-64
  71. Stergiou KD, Minopoulos GM, Memos VA, Stergiou CL, Koidou MP, Psannis KE. A Machine Learning-Based Model for Epidemic Forecasting and Faster Drug Discovery. Applied Sciences. 2022 Oct 24;12(21):10766.
  72. Sinha P, Kjelgaard MM, Gandhi TK, Tsourides K, Cardinaux AL, Pantazis D, Diamond SP, Held RM. Autism as a disorder of prediction. Proceedings of the national academy of sciences. 2014 Oct 21;111(42):15220-5.
  73. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases. 2003 Jul 1;37(1):113-28.
  74. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, De Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Soriano V, Walter H. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. Aids Rev. 2011 Apr 1;13(2):77-108.
  75. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H. Hepatitis C virus drug resistance and immune‐driven adaptations: relevance to new antiviral therapy. Hepatology. 2009 Apr;49(4):1069-82.
Personalized and Precision Medicine Journal
Volume 8, Issue 30 - Serial Number 30
Original article
Summer 2023
Pages 25-31

  • Receive Date 27 April 2023
  • Revise Date 11 June 2023
  • Accept Date 20 August 2023

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us